PPT-Reducing blockages in the pathway to Hepatitis C treatment
Author : sherrill-nordquist | Published Date : 2016-09-11
Emma Burke PHE Current London Picture Findings from the London Hepatitis C Snapshot Self reported by London Drug T reatment Commissioners Information received from
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Reducing blockages in the pathway to Hep..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Reducing blockages in the pathway to Hepatitis C treatment: Transcript
Emma Burke PHE Current London Picture Findings from the London Hepatitis C Snapshot Self reported by London Drug T reatment Commissioners Information received from 3132 boroughs Some form of pathway to HCV treatment in place in 20 boroughs but with widely varying strength of pathway. 10/23/12. Karla Thornton, MD, MPH. Division of Infectious Diseases. Department of Internal Medicine. UNM Health Sciences Center. kthornton@salud.unm.edu. Learning Objectives. Recognize the magnitude of the HCV epidemic and the consequences of not addressing the problem. Foundation for Faith Based Organizations. www.NYCHepBC.org. . Goals. To understand the liver and it’s role in the body. To understand liver health & disease. To understand Hepatitis C:. How it is Transmitted. Dr. Joanna Eveland, MS, MD. Clinical Chief for Special Populations, MNHC. O. bjectives. Understand recommendations for age cohort and risk based screening for Hepatitis C. Review strategies for health promotion and optimizing treatment readiness for HCV infected homeless individuals. HEPATITIS. Hepatitis. -Is inflammation of the liver. . (. itis. means inflammation and . Hepar. - Liver). Characterised. by irritation or swelling of liver cells(. hepatocytes. ). There are many forms of . . -Stacey . Trooskin. MD, PhD, Drexel University & . HepCAP. . -Karen Arendt, RN, St. Joseph's Center for Liver & Hepatobiliary Disease. -Courtney Jones, Patient Advocate Foundation. www.nvhr.org/program. Diana L. . Sylvestre. , MD. University of CA, San Francisco. OASIS Clinic, Oakland, CA. Disclosure Information. What’s New In Hepatitis C. Diana . Sylvestre. , MD. I have the following financial relationships to disclose:. ASSOC. PROF. DR. INGRID MIRON. What is Viral Hepatitis ?. . Viral hepatitis is a systemic disease with primary inflammation of the liver by any one of a . heterogenous. group of . hepatotropic. viruses. : inflammation of liver; presence of inflammatory cells in organ tissue. . Pathogenesis: Immune response.. Acute Viral Hepatitis. : symptoms last less than 6 months. Chronic Hepatitis. : Inflammation of liver for at least 6 months. Rachel Stallings, MPH. March 4, 2020. Hepatitis . Hepatitis = inflammation of the liver. Can be self-limiting or progress to fibrosis (scarring), cirrhosis, or liver cancer. . Causes:. Most commonly caused by a virus, there are 5: A, B, C, D & E. 1 Theme Bringinghepatitiscare closer to you SOCO Politicalcommitment for sustained andsimplified hepatitis testing, prevention and treatment services in tegrated into p rimary health care servi National Guidelines for Diagnosis & Management of Viral Hepatitis National Guidelines for PrefaceViral hepatitis is increasingly being recognized as a public health problem in India. While hepatitis A . TODAY. DIAGNOSIS. TREATMENT. SPECIAL SITUATIONS. COMPLICATIONS. VACCINATION. DIAGNOSIS. Time since infection. Relative amount. HBsAg. Anti-HBs. IgM anti-. HBc. Total anti-. HBc. Serological patterns of acute HBV infection. Navigating Hepatitis C: . What Patients Need to Know . avigating. Hepatitis C: . What Patients Need to Know. Need to Know. HCV Screening. Bruce Burkett. Executive Director. HepC Alliance. Persons who have ever injected illegal drugs, including those who injected only once many years ago. Jocelyn James, MD. Assistant Professor, Department of Medicine. University of Washington. . Adapted from slides developed in collaboration with Judith . Tsui. and the Washington State Department of Health.
Download Document
Here is the link to download the presentation.
"Reducing blockages in the pathway to Hepatitis C treatment"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents